<DOC>
	<DOC>NCT01632358</DOC>
	<brief_summary>The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.</brief_summary>
	<brief_title>Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Male and female patients 18 to 80 years (inclusive) of age. Patients are not treated for dyslipidemia with medications other than HMGCoA reductase inhibitors (statins) for at least 4 weeks prior to Day 1. Patients should be on stable doses of current medications, if any, for at least 3 months to be eligible. Patients must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 40 kg/m2. Use of other investigational drugs at the time of enrollment History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes Use of lipid modifying agents (e.g. fenofibrate, niacin, omega3 fatty acids, etc.) other than statins will exclude subjects. Pregnant or nursing (lactating) women Diabetic patients whose plasma glucose is not well controlled by stable diabetic treatment for at least 3 months Heavy smokers (smoke more than 10 cigarettes a day routinely and who cannot refrain from smoking during the study). Women of childbearing potential (WOCBP) can be included but must use highly effective contraception Significant illness within two (2) weeks prior to initial dosing History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>